Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02388165 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Open Posterior Spinal Fusion Procedures With Multilevel Instrumentation
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3,450
- Enrollment target
NCT02388165 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 3,450 participants.
The verdict
NCT02388165, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3,450 participants
- Enrollment target
Study Summary
The purposes of the clinical trial are to determine whether the SA4Ag vaccine can prevent postoperative Staphylococcus aureus infections in patients who are undergoing elective spinal fusion surgery, and to evaluate the safety of SA4Ag in patients who are undergoing elective spinal surgery.
Interventions
- OTHER Placebo
- BIOLOGICAL Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,450 participants |
| Start Date | 2015-07-02 |
| Est. Completion | 2019-06-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02388165
The ClinicalTrials.gov registry entry for NCT02388165 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3,450 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02388165 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02388165 about?
NCT02388165 is a clinical study titled "Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Open Posterior Spinal Fusion Procedures With Multilevel Instrumentation". The purposes of the clinical trial are to determine whether the SA4Ag vaccine can prevent postoperative Staphylococcus aureus infections in patients who are undergoing elective spinal fusion surgery, and to evaluate the safety of SA4Ag in patients who are undergoing elective spinal surgery.
What is the current status of trial NCT02388165?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3,450 participants. The study started on 2015-07-02. Estimated completion is 2019-06-27.
What interventions are being tested in trial NCT02388165?
The interventions under investigation include: Placebo (OTHER), Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT02388165?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.